SG Americas Securities LLC Purchases New Holdings in BeOne Medicines Ltd. – Sponsored ADR $ONC

SG Americas Securities LLC purchased a new stake in BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 2,787 shares of the company’s stock, valued at approximately $950,000.

Several other institutional investors also recently modified their holdings of ONC. Robeco Institutional Asset Management B.V. bought a new stake in shares of BeOne Medicines during the third quarter valued at approximately $228,000. WESPAC Advisors SoCal LLC acquired a new stake in BeOne Medicines during the third quarter worth $1,061,000. Retireful LLC bought a new stake in BeOne Medicines in the 3rd quarter valued at $321,000. Ethic Inc. bought a new stake in BeOne Medicines in the 3rd quarter valued at $325,000. Finally, FSM Wealth Advisors LLC acquired a new position in shares of BeOne Medicines in the 3rd quarter valued at $229,000. Institutional investors and hedge funds own 48.55% of the company’s stock.

Insiders Place Their Bets

In other news, SVP Chan Henry Lee sold 664 shares of the stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $331.76, for a total transaction of $220,288.64. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Xiaobin Wu sold 3,991 shares of BeOne Medicines stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $380.43, for a total value of $1,518,296.13. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 128,610 shares of company stock valued at $41,114,068 in the last 90 days. Insiders own 6.62% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Royal Bank Of Canada reiterated an “outperform” rating on shares of BeOne Medicines in a research report on Wednesday, December 17th. Zacks Research downgraded BeOne Medicines from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 28th. Citigroup upped their price objective on BeOne Medicines from $399.00 to $405.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Wall Street Zen upgraded BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research report on Friday, October 3rd. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $405.00 price target on shares of BeOne Medicines in a research note on Thursday, January 8th. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $378.43.

BeOne Medicines Stock Performance

NASDAQ ONC opened at $338.19 on Tuesday. BeOne Medicines Ltd. – Sponsored ADR has a 1-year low of $196.45 and a 1-year high of $385.22. The company has a 50 day moving average of $330.41 and a 200-day moving average of $317.93. The company has a current ratio of 2.39, a quick ratio of 2.17 and a debt-to-equity ratio of 0.03. The firm has a market cap of $37.09 billion, a price-to-earnings ratio of 663.12 and a beta of 0.47.

BeOne Medicines Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.